Here's Pfizer's Motivation Behind Its Biggest Takeover In 3 Years.

Autor:	GATLIN, ALLISON (AUTHOR)
Předmět:	PFIZER Inc., COLON cancer treatment
Zdroj:	Investors Business Daily. 6/19/2019, pN.PAG-N.PAG. 1p.
Abstrakt:	The article discusses the decision by pharmaceutical company Pfizer to acquire biotech company Array BioPharma in 2019. According to GlobalData analyst Tajekesa Chapman, the merger has a huge potential for Pfizer because a combination of two drugs, Braftovi and Mektovi, are being tested for treating cancer such as non-small cell lung cancer, hematological cancers and solid tumors. The combined drugs generated 35.1 million in sales in the U.S. during the quarter ended March 31, 2019.
Databáze:	Regional Business News
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.